4.5 Article

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2017 EXECUTIVE SUMMARY

期刊

ENDOCRINE PRACTICE
卷 23, 期 2, 页码 207-238

出版社

ELSEVIER INC
DOI: 10.4158/EP161682.CS

关键词

-

资金

  1. AstraZeneca
  2. Janssen Pharmaceuticals, Inc.
  3. Lexicon Pharmaceuticals, Inc.
  4. Merck Co.
  5. Novo Nordisk
  6. Sanofi
  7. Amgen
  8. Boehringer Ingelheim
  9. Takeda
  10. Janssen
  11. Eli Lilly
  12. Eisai
  13. Asahi
  14. Abbott
  15. Endo Barrier
  16. Bayer
  17. Gilead
  18. Merck
  19. Weight Watchers
  20. Lexicon
  21. Pfizer
  22. Elcelyx
  23. Medtronic
  24. Regeneron
  25. BI
  26. Esperion
  27. Grifols
  28. Hamni
  29. GlaxoSmithKline
  30. Novartis
  31. Dexcom
  32. Bristol Myers Squibb
  33. Ionis
  34. Orexigen

向作者/读者索取更多资源

This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据